bioAffinity Technologies Inc. reported total revenue of $1.5 million for the third quarter ended September 30, 2025, down from $2.4 million in the same period of 2024, primarily due to the discontinuation of unprofitable pathology services. CyPath Lung testing revenue for the quarter increased approximately 122% year-over-year, reflecting higher physician adoption and test volume. Net loss for the quarter was $5.1 million, or $4.74 per share, compared to a net loss of $2.0 million, or $4.84 per share, in the third quarter of 2024, mainly due to the change in fair value of warrants issued. Operating expenses fell 16% year-over-year to $3.7 million, while depreciation and amortization expense declined 25% to $113,000. Cash and cash equivalents rose to $7.7 million as of September 30, 2025, following $10.4 million in gross proceeds from equity transactions. Sales of CyPath Lung reached a record high in the third quarter, increasing 92% over the previous quarter, with notable growth in adoption by VA hospitals and in the mid-Atlantic region.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114274995) on November 14, 2025, and is solely responsible for the information contained therein.
Comments